摘要
Abstract
OBJECTIVE: To evaluate the therapeutic efficacy and safety of new mucolytic agent vs. ambroxol on eliminating phlegm for chronic respiratory disease. METHODS: Random controlled trails of new mucolytic agent vs. ambroxol on eliminating phlegm for chronic respiratory disease were gathered from Cochrane library, PubMed, EMbase, ISI, CBM, CNKI, VIP, Wanfang database; Methodology quality evaluation and Meta-analysis of included studies were conducted. RESULTS: 5 RCT with a total of 537 patients were included.Meta-analysis showed that the control of phlegm properties [RR=1.00, 95%CI(0.74, 1.34), P=0.98], sputum quantity [RR=1.07, 95%CI(0.91, 1.25), P=0.42], cough frequency [RR=0.88, 95%CI(0.60, 1.29), P=0.52] total effective rate [RR=1.02, 95%CI(0.93, 1.12), P=0.69] of new mucolytic agent group was better than that of ambroxol group,while the degree of sputum [RR=0.93, 95%CI(0.69, 1.24), P=0.61] was lower than that of ambroxol group, but there was no statistical significance in 2 groups; there was no statistical significance in the difference of ADR. CONCLUSION: New mucolytic agent could relieve difficult coughing due to chronic respiratory disease with sound clinical efficacy and slight adverse drug reaction.关键词
厄多司坦/福多司坦/氨溴索/Meta分析Key words
Erdosteine/ Fudosteine/ Ambroxol/ Meta-analysis分类
医药卫生
